This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QLT Announces Completion Of US$200 Million Special Cash Distribution To Shareholders

VANCOUVER, British Columbia, June 27, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (" QLT" or the " Company") is pleased to announce that the Company has completed today the previously announced special cash distribution (the " Cash Distribution") in the amount of US$200 million, by way of a reduction of the capital of the Company's common shares (the " Shares"). As a result, QLT's shareholders as of June 24, 2013, the record date for the distribution (the " Record Date"), received a special cash distribution payment of US$3.915283 per Share (the " Distribution Payment"). The Distribution Payment per Share was determined based on the number of issued and outstanding Shares of the Company as of the Record Date. As previously announced, the Distribution Payments to shareholders were made without Canadian withholding taxes of up to 25% being payable, pursuant to an Advance Tax Ruling received from Canadian tax authorities.

"Acting in the best interests of our shareholders, your Board is very pleased to complete this unprecedented return of $200 million by way of such an exceptionally tax-efficient capital reduction," said Mr. Jason M. Aryeh, Chairman of the Board.

The Distribution Payments were processed through the Company's disbursing agent, Computershare Investor Services Inc. As previously announced, in accordance with the applicable rules of the Toronto Stock Exchange and NASDAQ rules, "due bill" trading procedures were applied in connection with the Cash Distribution in the period from June 20, 2013 to June 27, 2013. The Shares will commence trading on an "ex-distribution" basis on June 28, 2013. 

About QLT

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs